Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 269 citing articles:

Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
Samuel M. S. Cheng, Chris Ka Pun Mok, Yonna W. Y. Leung, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 486-489
Open Access | Times Cited: 354
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study
Alejandro Jara, Eduardo A. Undurraga, José R. Zubizarreta, et al.
The Lancet Global Health (2022) Vol. 10, Iss. 6, pp. e798-e806
Open Access | Times Cited: 192
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 178
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
Jingxin Li, Lihua Hou, Xiling Guo, et al.
Nature Medicine (2022) Vol. 28, Iss. 2, pp. 401-409
Open Access | Times Cited: 140
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Otávio T. Ranzani, Matt D. T. Hitchings, Rosana Leite de Melo, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 89
Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
Xiaoqi Yu, Dong Wei, Wenxin Xu, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 80
An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines
Saeed Khoshnood, Maniya Arshadi, Sousan Akrami, et al.
Journal of Clinical Laboratory Analysis (2022) Vol. 36, Iss. 5
Open Access | Times Cited: 65
CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
Lairun Jin, Zhuopei Li, Xiaoyin Zhang, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 6
Open Access | Times Cited: 61
A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines
Joey Ming Er Lim, Shou Kit Hang, Smrithi Hariharaputran, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100793-100793
Open Access | Times Cited: 60
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
Suvichada Assawakosri, Sitthichai Kanokudom, Nungruthai Suntronwong, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 8, pp. 1372-1381
Open Access | Times Cited: 57
The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants
Yuxin Chen, Lin Chen, Shengxia Yin, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 1524-1536
Open Access | Times Cited: 51
Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization
Zhangkai J. Cheng, Huimin Huang, Peiyan Zheng, et al.
Allergy (2022) Vol. 77, Iss. 8, pp. 2404-2414
Open Access | Times Cited: 48
Microbiota and COVID-19: Long-term and complex influencing factors
Jiaqi Gang, Haiyu Wang, Xiangsheng Xue, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 48
Covid-19: virology, variants, and vaccines
Megan Young, Harry Crook, J. T. Scott, et al.
BMJ Medicine (2022) Vol. 1, Iss. 1, pp. e000040-e000040
Open Access | Times Cited: 44
Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study
Jingwen Ai, Yi Zhang, Haocheng Zhang, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 639-647
Open Access | Times Cited: 41
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
Nádia Emi Aikawa, Léonard de Vinci Kanda Kupa, Ana Cristina de Medeiros Ribeiro, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 7, pp. 1036-1043
Open Access | Times Cited: 40
Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change
Tamàs Fülöp, Anis Larbi, Graham Pawelec, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 607-607
Open Access | Times Cited: 40
Herd Immunity to Fight Against COVID-19: A Narrative Review
Yasha N Suryawanshi, Dalia Biswas
Cureus (2023)
Open Access | Times Cited: 34
Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicine
Ling Ye, Shicheng Fan, Pengfei Zhao, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 9, pp. 3598-3637
Open Access | Times Cited: 31
Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron
Yuchen Wei, Katherine Min Jia, Shi Zhao, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e2254777-e2254777
Open Access | Times Cited: 29
What makes SARS‐CoV‐2 unique? Focusing on the spike protein
Jingbo Qian, Shi-Chang Zhang, Fang Wang, et al.
Cell Biology International (2024) Vol. 48, Iss. 4, pp. 404-430
Open Access | Times Cited: 13
Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine
Zhifei Chen, Fangqin Xie, Hairong Zhang, et al.
Frontiers in Public Health (2025) Vol. 13
Open Access | Times Cited: 1
Self-Amplifying RNA: Advantages and Challenges of a Versatile Platform for Vaccine Development
Thomas Vallet, Marco Vignuzzi
Viruses (2025) Vol. 17, Iss. 4, pp. 566-566
Open Access | Times Cited: 1
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial
Xuanyi Wang, Syed Faisal Mahmood, Fang Jin, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 1910-1919
Open Access | Times Cited: 38
Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
Jie Deng, Yirui Ma, Qiao Liu, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 17, pp. 10752-10752
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top